Split History
ETFs Holding ALPN »    ALPN Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Alpine Immune Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Co.'s ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Co.'s ALPN-303 is a dual B cell cytokine antagonist, being developed for the treatment of B cell mediated inflammatory and autoimmune diseases. Co.'s primary oncology program is ALPN-202 (davoceticept) is a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. According to our ALPN split history records, Alpine Immune Sciences has had 1 split.
ALPN split history picture
Alpine Immune Sciences (ALPN) has 1 split in our ALPN split history database. The split for ALPN took place on July 25, 2017. This was a 1 for 4 reverse split, meaning for each 4 shares of ALPN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.

When a company such as Alpine Immune Sciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ALPN split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Alpine Immune Sciences shares, starting with a $10,000 purchase of ALPN, presented on a split-history-adjusted basis factoring in the complete ALPN split history. ALPN split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/18/2015
End date: 09/30/2022
Start price/share: $59.00
End price/share: $7.20
Dividends collected/share: $0.00
Total return: -87.80%
Average Annual Total Return: -25.06%
Starting investment: $10,000.00
Ending investment: $1,220.71
Years: 7.29
Date Ratio
07/25/20171 for 4
ALPN is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ALQA Split History
ALR Split History
ALT Split History
ALVR Split History
ALXA Split History
ALXN Split History
AMDA Split History
AMED Split History
AMGN Split History
AMN Split History

Also explore: ALPN shares outstanding history

Email EnvelopeFree ALPN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

American Virtual Cloud Technologies, Inc. (AVCT)
Avenue Therapeutics, Inc. (ATXI)
Annaly Capital Management, Inc. (NLY)
CohBar, Inc. (CWBR)
TOP Ships Inc. (TOPS)
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Nabriva Therapeutics plc (NBRV)
NeuroBo Pharmaceuticals, Inc. (NRBO)
First Wave BioPharma, Inc. (FWBI)
Palatin Technologies, Inc. (PTIN)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ALPN Insider Buying

ALPN Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.